Literature DB >> 12214893

Safety of chewable tablets for children.

Theresa M Michele1, Barbara Knorr, Elizabeth B Vadas, Theodore F Reiss.   

Abstract

New emphasis on pediatric drug development makes the availability of safe, easy-to-use dosage formulations imperative for clinical practice. Chewable tablets are a widely used pediatric dosage form; however, a literature review on the safety of this formulation has not been published. We have, therefore, determined the safety of chewable tablets in the pediatric age group based on the published literature. A search of safety information on chewable tablets was performed from the published literature dating from January 1966 to January 1999. Search terms included tablet, chewable tablet, drug formulation, aspiration, choking, asphyxia, airway obstruction, and foreign body. Additional information was obtained from the Physician's Desk Reference, by purchasing products at a local drug store, from calls to manufacturers, and from the IMS Health National Prescription Audit Plus 7. Human, English-language studies of two types were included, clinical articles with any mention of chewable tablets, and aspiration case series. The results of this review showed that more than 60 chewable tablet formulations are approved for use in the United States. Medical issues, including foreign-body injuries, related to the chewable-tablet formulation were extremely rare. The advantages of chewable tablets include palatability, stability, precise dosing, portability, and ease of delivery. It is concluded that the available literature suggests that chewable tablets provide a safe, well-tolerated alternative to traditional pediatric drug formulations and offer significant advantages in children 2 years of age and older.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12214893     DOI: 10.1081/jas-120004032

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  8 in total

1.  Changes in availability of paediatric medicines in Australia between 1998 and 2002.

Authors:  Jocelyn Chui; June Tordoff; David Reith
Journal:  Br J Clin Pharmacol       Date:  2005-06       Impact factor: 4.335

2.  Variation in captopril formulations in pharmacies across Canada.

Authors:  Mihir Dipakkumar Bhatt; Jason E Thomas; Tapas Kumar Mondal
Journal:  Paediatr Child Health       Date:  2011-04       Impact factor: 2.253

3.  A chewable pediatric preparation of ibuprofen is palatable and acceptable to children.

Authors:  Steven Barnett; Aomesh Bhatt
Journal:  Paediatr Neonatal Pain       Date:  2020-02-10

Review 4.  Patient-centred pharmaceutical design to improve acceptability of medicines: similarities and differences in paediatric and geriatric populations.

Authors:  Fang Liu; Sejal Ranmal; Hannah K Batchelor; Mine Orlu-Gul; Terry B Ernest; Iwan W Thomas; Talia Flanagan; Catherine Tuleu
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

Review 5.  Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms.

Authors:  Felipe L Lopez; Terry B Ernest; Catherine Tuleu; Mine Orlu Gul
Journal:  Expert Opin Drug Deliv       Date:  2015-07-13       Impact factor: 6.648

6.  Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.

Authors:  Sharon B Wigal; Ann Childress; Sally A Berry; Heidi Belden; Faith Walters; Phillip Chappell; Nancy Sherman; John Orazem; Donna Palumbo
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-05-30       Impact factor: 2.576

7.  Oral medicines for children in the European paediatric investigation plans.

Authors:  Diana A van Riet-Nales; Erwin G A W Römkens; Agnes Saint-Raymond; Piotr Kozarewicz; Alfred F A M Schobben; Toine C G Egberts; Carin M A Rademaker
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

8.  Acceptability of Mebendazole Chewable Tablet in Children Aged 2 to 4 Years in Peru.

Authors:  Fernando Perez; Thibault Vallet; Zarela Bravo; Kristin Callahan; Fabrice Ruiz
Journal:  Pharmaceutics       Date:  2021-12-23       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.